

Special Issue

Malignant and Potentially Malignant Disorders of the Oral Cavity: Updates from Pathogenesis to Therapy 2.0

Message from the Guest Editors

This Special Issue, “Malignant and Potentially Malignant Disorders of the Oral Cavity: Updates from Pathogenesis to Therapy”, will focus on the pathophysiology, diagnosis, prognosis, and therapy of malignant and potentially malignant disorders of the oral cavity, but will not be limited to only these aspects. Oral squamous cell carcinoma (OSCC) represents the most frequent malignant tumor of the oral cavity. Often, OSCC derives from oral potentially malignant disorders (OPMD), including mucosal lesions, which have a greater chance of transforming into cancer, e.g., oral leukoplakia, oral erythroplakia, palatal lesions in reverse smokers, oral lichen planus, oral submucous fibrosis, actinic keratosis, and discoid lupus erythematosus. No reliable prognostic factor nor treatment is currently available to avoid their risk of malignant transformation, and the need to clarify the “field cancerization” process is urgent.

Oral conditions and their associations with other systemic malignant and chronic inflammatory diseases will be considered as well.

Guest Editors

Dr. Elena Varoni

Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy

Dr. Lia Rimondini

Department of Health Sciences, University of Piemonte Orientale “UPO”, Vercelli, Italy

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/136302

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).